Figure 1.
Rechallenge with a different immune checkpoint inhibitor (ICI) anti-PD1 immunotherapy, nivolumab, did not lead to a recurrence of ICI-associated renal tubular acidosis (ICI-RTA).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.